ACT Advisors’s Cidara Therapeutics CDTX Stock Holding History

ACT Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-693	Closed	-$10.5K	–	30
2022 Q4	$10.5K	Buy	+693	New	+$8.27K	0.01%	32

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

ACT Advisors's CDTX Position: Q1 2023 in Review

ACT Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2023, closing a stake of 693 shares — an estimated $10.5K sold.

ACT Advisors first reported a position in CDTX in Q4 2022 and held it in 1 quarter. The position peaked at $10.5K in Q4 2022. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2023.

ACT Advisors reported no remaining Cidara Therapeutics position as of Q1 2023 after selling out during the quarter.
ACT Advisors sold 693 Cidara Therapeutics shares in Q1 2023, an estimated $10.5K.
ACT Advisors first reported a position in Cidara Therapeutics in Q4 2022 and held it in 1 quarter.
ACT Advisors's Cidara Therapeutics position peaked at $10.5K in Q4 2022.
54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2023.

Based on ACT Advisors's 13F filing for Q1 2023, filed 26 Apr 2023.